University administers first doses of mRNA HIV vaccine through Moderna partnership

February 7, 2022

George Washington University has collaborated with Moderna to test the safety of the first mRNA HIV vaccines and the immune responses of two participants in the Phase 1 clinical trial. Four institutions, including GW, have enrolled 56 HIV-negative adult participants for the vaccines’ clinical trials. The mRNA HIV vaccine aims to block the replication of HIV strains and stimulate the production of broadly neutralizing antibodies that control the virus within HIV-positive patients’ immune systems. Read more by clicking the link!

Latest News

August 31, 2023
George Washington's Vaccine Research Unit is participating in the Project NextGen clinical study. Read this article on the journey to preparing the vaccines and treatments for the next outbreak.
April 20, 2023
Read more information about how The George Washington Vaccine Research Unit is looking for adolescents between the ages of 12 and 17 to participate in a Mpox vaccine trial. The need for adolescents is vital for researchers to get an approved vaccine for adolescents to prevent another outbreak.
December 8, 2022
Read more about the new hope found in Phase 1 clinical trials for the HIV vaccine.